Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, ...

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center and VERIFY investigator, speaks to the impressive ...

The starting dosage for myelofibrosis depends on your platelet count, as outlined in the following table. Note that platelets are measured per liter (L) of blood. Jakafi is approved to treat acute ...

FRIDAY, April 4, 2025 (HealthDay News) -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) enhances risk stratification, ...

You also may need the test because: High hemoglobin, especially in polycythemia vera, is often treated with therapeutic phlebotomy. This involves removing a unit of blood, similar to making a blood ...

High MCH values may indicate macrocytic anemia as well as conditions like polycythemia vera or a deficiency of vitamin B12 and folic acid. Your healthcare provider can diagnose the cause with the MCH ...